On November 22, 2021 Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, reported that it has signed agreements to acquire Centro Oncológico de Antioquia (COA) and Clínica Clofán, further expanding the company’s presence in Colombia (Press release, Fresenius, NOV 22, 2021, View Source [SID1234595954]). The clinics, located in Colombia’s second largest city Medellín, will become part of Quirónsalud’s existing healthcare network in the country, which already comprises six hospitals and ten diagnostic centers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

COA is specialized in the diagnosis and treatment of cancer. It has 75 beds, four operating rooms, and specialized centers for nuclear medicine, radiotherapy and bone marrow transplants. Clínica Clofán is the second largest ophthalmic center in the city, with ten operating rooms and further dedicated facilities for treating even severe ophthalmic diseases and performing complex procedures.

Both clinics offer state-of-the-art medical standards and technology to their patients and are regarded as leading medical facilities with highly renowned physicians. Together they generate sales of around €30 million.

The acquisition is another important step in strengthening Fresenius Helios’ presence in the growing and consolidating healthcare services markets in Latin America.

The transaction is expected to close in the first quarter of 2022, pending anti-trust clearance of the Colombian authorities. Fresenius Helios expects the acquisition to be accretive to Fresenius’ Group net income already in fiscal year 2022.